MONROVIA, Calif., Nov. 8, 2017 /PRNewswire/ -- Xencor, Inc.
(NASDAQ: XNCR), a clinical-stage biopharmaceutical company
developing engineered monoclonal antibodies for the treatment of
autoimmune diseases, asthma and allergic diseases and cancer, today
announced that data from preclinical studies of XmAb®20717, a PD1 x
CTLA4 dual checkpoint inhibitor, and XmAb®23104, a PD1 x ICOS
bispecific antibody candidate, will be presented at the Society for
Immunotherapy of Cancer (SITC) 2017 Annual Meeting taking place
November 8-12, 2017. Abstracts are
available on the SITC 2017 website at:
https://www.sitcancer.org/2017/abstracts/info.
Poster # P329
Presentation Date/Time:
Friday, November 10, 12:30 –
2:00 p.m. and 6:30 – 8:00 p.m. ET
Title: Dual blockade of PD1 and CTLA4 with bispecific
antibody XmAb20717 promotes human T-cell activation and
proliferation
- PD1 x CTLA4 bispecific antibody produced using Xencor's
bispecific platform
- Goal is selective targeting of PD1+CTLA4+ tumor-infiltrating
lymphocytes for improved therapeutic window vs combination
checkpoint blockade
- Comparable T-cell activation to a combination of bivalent
antibodies targeting PD1 and CTLA4
- Specific targeting of human lymphocytes positive for both PD1
and CTLA4 potentially could promote similar efficacy compared to a
combination of bivalent antibodies while reducing adverse
events
- Data suggest that clinical development is warranted for the
treatment of human malignancies
Poster # P347
Presentation Date/Time:
Friday, November 10, 12:30 –
2:00 p.m. and 6:30 – 8:00 p.m. ET
Title: Anti-PD1 x anti-ICOS bispecific antibody XmAb23104
brings together PD1 blockade and ICOS costimulation to promote
human T cell activation and proliferation
- Anti-PD1 x anti-ICOS bispecific antibody produced using
Xencor's bispecific platform
- Goal is to engage T cell costimulatory receptors in concert
with checkpoint blockade to further increase T-cell activation and
proliferation
- XmAb23104 brings together PD1 blockade and ICOS costimulation
and promotes strong T-cell activation in vitro and in
vivo
- Compelling activity suggests clinical development is warranted
for the treatment of human malignancies
Posters are available on the investor relations section of the
Xencor website under events and presentations at
www.xencor.com.
Xencor's Analyst & Investor Event at SITC 2017 Annual
Meeting
Xencor will host an analyst and investor event at
the SITC 2017 Annual Meeting on Saturday,
November 11, 2017 from 12:00 to 2:00
p.m. ET in the Gaylord National Resort & Convention
Center, with formal presentations beginning at 12:30 p.m. ET. The event will feature a
discussion on Xencor's tumor microenvironment targeting bispecific
oncology pipeline, including XmAb®20717, XmAb®22841, XmAb®23104,
and new bispecific molecules. The event will be webcast live and
can be accessed under the "Events & Presentations" section in
the Investors section of the Xencor website at www.xencor.com. The
webcast will be archived on the Company website for 30
days.
About Xencor's XmAb® Bispecific
Technology
As opposed to traditional monoclonal antibodies that target and
bind to a single antigen, bispecific antibodies are designed to
elicit multiple biological effects that require simultaneous
binding to two different antigen targets. Xencor's XmAb
bispecific Fc domain technology is designed to maintain full-length
antibody properties in a bispecific antibody, potentially enabling
favorable in vivo half-life and simplified manufacturing.
Efforts at bispecific antibody design are typically frustrated
by poor molecular stability, difficulties in production and short
in vivo half-life. Xencor has engineered a series of Fc
domain variants that spontaneously form stable, heterodimeric
bispecific antibodies and that can be made and purified with
standard antibody production methods. These bispecific Fc domains
are used to generate a broad array of novel drug candidates in a
range of molecule formats.
About Xencor, Inc.
Xencor is a clinical-stage
biopharmaceutical company developing engineered monoclonal
antibodies for the treatment of autoimmune diseases, asthma and
allergic diseases and cancer. Currently, 11 candidates engineered
with Xencor's XmAb® technology are in clinical
development internally and with
partners. Xencor's internal programs include: XmAb®5871
in Phase 2 development for the treatment of IgG4-Related Disease,
and also for the treatment of Systemic Lupus Erythematosus;
XmAb®7195 in Phase 1 development for the treatment of asthma and
allergic diseases; XmAb®14045 in Phase 1 development for acute
myeloid leukemia; XmAb®13676 in Phase 1 development for B-cell
malignancies; XmAb®18087 in pre-clinical development for the
treatment of neuroendocrine tumors; and XmAb®20717 in pre-clinical
development for the treatment of multiple
cancers. Xencor's XmAb antibody engineering technology
enables small changes to the structure of monoclonal antibodies
resulting in new mechanisms of therapeutic
action. Xencor partners include Novartis, Amgen,
MorphoSys, Merck, CSL/Janssen, Alexion and Boehringer
Ingelheim. For more information, please
visit www.xencor.com.
Forward Looking Statements:
Statements contained in
this press release and the related abstracts and presentations
regarding matters that are not historical facts are forward-looking
statements within the meaning of applicable securities laws,
including any expectations relating to our business, research and
development programs, including XmAb20717 and XmAb23104, partnering
efforts or our capital requirements. Such statements involve known
and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements and the timing
of events to be materially different from those implied by
such statements, and therefore these statements should not be read
as guarantees of future performance or results. Such risks include,
without limitation, the risks associated with the process of
discovering, developing, manufacturing and commercializing drugs
that are safe and effective for use as human therapeutics and other
risks described in Xencor's public securities filings.
All forward-looking statements are based
on Xencor's current information and belief as well as
assumptions made by Xencor. Readers are cautioned not to place
undue reliance on such statements and Xencor disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/xencor-to-present-preclinical-data-on-tumor-microenvironment-targeting-bispecifics-xmab20717-and-xmab23104-at-society-for-immunotherapy-of-cancer-sitc-2017-annual-meeting-300551653.html
SOURCE Xencor, Inc.